Global Fund

The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) was created to dramatically increase resources to fight three of the world's most devastating diseases, and to direct those resources to areas of greatest need. As a partnership between governments, civil society, the private sector and affected communities, the Global Fund represents an innovative approach to international health financing.

GFATM Support to the Kenya

Kenya is among the beneficiaries of the GFATM. Under the Tuberculosis component, the country has benefited from the round 2, 5 and 6 below is summary of the impact of the utilization of the GFATM funds.

Impact of global fund in Kenya

Round

Amount budgeted (USD)

Amount received (%) (USD)

Amount spent
(%)
(USD)

Life span remaining

2

8,623,253

3,556,121(41)

2,276,291(64)

1 year

5

19,899,621

3,511,242(17.6)

2,162,607(61)

4 years

6

26,964,867

Nil

Nil

5 years

This support has enabled the division of TB and leprosy control to carry out the following activities

  1. Provide transport to facilitate distribution of drugs and supervision of treatment for the two diseases
  2. Capacity building of staffs providing TB services to enable them to offer new TB packages especially TBHIV services, community involvement in TB control and in monitoring and evaluation
  3. Support commodity security in terms of procurement of Cortimoxazole, laboratory reagents and first line and second line anti-TB drugs
  4. To support mass media and community social mobilization for TB control

 
The main achievements  

Activity

Specific item

Achievements

Provision of transport

Vehicles

8 vehicles procured

Bicycles

780 bicycles procured

Motor bikes

15 motor bikes procured

Training

Health care workers

2,541health workers trained

Community health care workers
(CHWs)

1,182 CHWs trained

New initiatives supported

TBHIV programme

Rolled out country wide. Now 79% of our patients access TBHIV services

Community DOTS

Programme rolled out in 31 districts

Purchase of TB drugs

First line

40,000 anti-TB patient packs bought 

Second line

Drugs for 40 MDRTB patients purchased

Cortimoxazole

Cortimoxazole available

Laboratory support

Renovation of laboratories

13 laboratories renovated and in use

Microscopes

100 microscopes bought

Reagents

Lab reagents procured in 2005, 2006 and 2007

Advocacy

Mass media

TV  and radio campaigns in 2004, 2005 and 2007

Sensitization of local leaders

1,753 leaders sensitized